JO
CYTK icon

John Overdeck’s Cytokinetics CYTK Stock Holding History

John Overdeck’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,000
Closed -$1.25M – 3075
2023
Q4 		$1.25M Buy
+15,000
New +$543K ﹤0.01% 1943

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's CYTK Position: Q2 2026 in Review

John Overdeck increased its Cytokinetics (CYTK) stake by 11% in Q2 2026, buying an estimated $2.33M and bringing the position to 317,411 shares worth $27M. The position accounts for 0.02% of the portfolio, ranked #867.

John Overdeck first reported a position in CYTK in Q3 2013 and has held it in 43 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • John Overdeck held 317,411 shares of Cytokinetics worth $27M as of Q2 2026.
  • John Overdeck bought 32,403 Cytokinetics shares in Q2 2026, an estimated $2.33M.
  • Cytokinetics made up 0.02% of John Overdeck's portfolio in Q2 2026, its #867 holding.
  • John Overdeck first reported a position in Cytokinetics in Q3 2013 and has held it in 43 quarters since.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.